Compare MPU & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPU | SCLX |
|---|---|---|
| Founded | 1989 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | 30 |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.8M | 52.9M |
| IPO Year | 2023 | N/A |
| Metric | MPU | SCLX |
|---|---|---|
| Price | $0.73 | $6.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 47.1K | 34.0K |
| Earning Date | 03-09-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $122.52 |
| Revenue Next Year | N/A | $186.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $3.60 |
| 52 Week High | $4.44 | $34.27 |
| Indicator | MPU | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 43.58 | 37.41 |
| Support Level | $0.72 | $6.20 |
| Resistance Level | $0.81 | $7.76 |
| Average True Range (ATR) | 0.04 | 0.67 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 53.54 | 56.46 |
Mega Matrix Inc is a holding company. It operates through its two subsidiaries Mega Metaverse Corp (Mega) and JetFleet Management Corp (JMC). The Company has two business segments which are comprised of : ETH staking business and The leasing of regional aircraft to foreign and domestic regional airlines. The majority of the company's revenue is earned through Leasing business segment. The company operates in USA and Canada, Asia-Pacific, Europe, Middle East and Africa, and Latin America.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.